AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03996863 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo device
Description: Participants during infusion following chemotherapy will wear the placebo device set at low power (6 decibels lower than normal power, ineffective power) for four days following treatment and nausea outcomes will be recorded by questionnaire or by the investigator during site visits.
Study NCT02710708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EE20/DRSP (YAZ, BAY86-5300)
Description: YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
Study NCT00478738 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: GSK961081
Study NCT02547922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
Study NCT02547922 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
Study NCT00362778 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Insulin
Description: intravenous continuous insulin infusion for 48 hours
Study NCT01832467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab-containing chemotherapy
Study NCT05007678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leflunomide
Description: leflunomide administered orally; daily loading dose of 100mg for 3 days, followed by a daily maintenance dose 10-20mg daily, to a total course of 10 days
Study NCT04297306 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Prescription
Description: Standardised Exercise Prescription.
Study NCT04297306 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Exercise Prescription and Virtual Reality Exercise Gaming support
Description: Standardised Exercise Prescription with the additional support of Virtual Reality Promoted Exercise Games.
Study NCT00781599 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chantix
Description: Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
Study NCT00781599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chantix
Description: Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
Study NCT00781599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adherence Counseling
Description: Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.
Study NCT00781599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Counseling
Description: Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
Study NCT00781599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Counseling
Description: Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
Study NCT01403701 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: pelvic floor physical therapy
Study NCT01106625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
Study NCT01106625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
Study NCT01106625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: The patient's stable dose of background metformin therapy should be continued throughout the study.
Study NCT01106625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: The patient's stable dose of background metformin therapy should be continued throughout the study.
Study NCT01106625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulphonylruea
Description: The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
Study NCT01106625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sulphonylruea
Description: The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
Study NCT05271422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Real Pulse Electrical Stimulation (NuEyne 01)
Description: Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
Study NCT05271422 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulse Electrical Stimulation
Description: Patients wear our clinical trial device 15\~30 mins once a day for 14 days and once a week from the 15th day to the 12th week.
Study NCT00736866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Description: Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
Study NCT00736866 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
Study NCT00947752 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glatiramer Acetate
Description: Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
Study NCT00947752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental Glatiramer Acetate
Description: GA 20 mg/0.5 mL
Study NCT06409091 — intervention group
Intervention type: DEVICE
Intervention: Medium weight or Heavy weight mesh
Description: Patients received a hernia repair with one of the two groups
Study NCT03489135 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReVene Thrombectomy Catheter
Description: Endovascular treatment of an acute iliofemoral DVT
Study NCT02299245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: different dose of rosuvastatin treatment
Study NCT02299245 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin
Description: different dose of rosuvastatin treatment
Study NCT04260958 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise-based cardiac rehabilitation
Description: The exercise program (remote/centre-based) will be standardized. An exCR-program is defined as at least 24 supervised sessions, with a total session length of 60 minutes, for at least 3 months, with possibility to complete missed sessions the 4th month. Each exercise session includes at least 20 min of aerobic exercise, intensity 13-17 on Borg´s rating of perceived exertion (RPE)-scale ≈ 60% - 85% of VO2max or 70 - 95% of maximal heart rate. In addition, each exercise session includes 1-3 sets of 8-10 upper and/or lower limb exercises in 10-15 repetitions, 40-80% of 1 repetition maximum. Attending ≥75% of the 24 sessions over a 4-month period will be considered as successful.
Study NCT01855984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral mixed tocotrienols
Description: 200mg per day
Study NCT01855984 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
Study NCT04445909 — intervention group
Intervention type: DEVICE
Intervention: VA-ECMO
Description: Deployment of extracorporeal membrane oxygenation cardiac assist device.
Study NCT02563015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: liquid drops
Study NCT04627298 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: educational video game for preteens to support HPV vaccination
Description: An educational video game developed for 11-12 year olds to increase interest in and decision to pursue HPV vaccination.
Study NCT03378726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micronutrients
Description: Micronutrient powder is the current supplement provided by the Colombian Ministry of Health and Social Protection to children between 1 and 5 years of age.
Study NCT03378726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SPOON Group Counseling
Description: SPOON group counseling is an innovative behavior change strategy in which participants will learn information related to child health and nutrition in a group format.
Study NCT03378726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interpersonal Counseling
Description: SPOON interpersonal counseling is an innovative behavior change strategy in which participants will learn information via one-on-one sessions with the instructor.
Study NCT03378726 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: SQ-LNS
Description: SQ-LNS is a peanut-based dietary supplement that has been shown to increase children's height and weight in several studies in Africa.
Study NCT03378726 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Counseling
Description: Standard counseling refers to the counseling currently provided by health personnel to women and children in the selected intervention area of Colombia
Study NCT01260376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acipimox
Description: Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
Study NCT02287441 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tomato
Description: Tomato Products (tomato)
Study NCT02287441 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Raw
Description: Vegetables Prepared Raw (raw).
Study NCT03697655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab 20 MG/ML [Darzalex]
Description: Daratumumab dose 16 mg/kg body weight to be administered as an IV infusion. treatment given until clinical progression or SPR but no longer than 73 weeks
Study NCT04410510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Et (Caesalpinia spinosa extract)
Description: P2Et active extract capsule equivalent to 250mg of P2Et every 12 hours for 14 days + Standard Care
Study NCT04410510 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule equivalent to 250mg of excipients of P2Et every 12 hours for 14 days + Standard Care
Study NCT00712335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate
Description: DPI 250 mcg BID for 3 weeks
Study NCT00712335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate
Description: DPI 250 mcg BID for 3 weeks
Study NCT00712335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: PO 10 mg QHS for 3 weeks
Study NCT00712335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: PO 10 mg QHS for 3 weeks
Study NCT00712335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: DPI 50mg BID for 3 weeks
Study NCT00712335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: DPI 50mg BID for 3 weeks
Study NCT01867632 — intervention group
Intervention type: DEVICE
Intervention: Acellular Dermal Matrix
Study NCT02509585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tc99m tilmanocept
Description: A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally no more than 20 hours before surgery
Study NCT03738111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG02 Citrate
Description: TG02 citrate capsules
Study NCT03946046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical targeting
Description: The intervention consists of the injection of botulinum toxin A into muscles targeted by a clinical localization method (observation and palpation of target muscles)
Study NCT03946046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasonography targeting
Description: The intervention consists of the injection of botulinum toxin A into muscles by ultrason-guided method
Study NCT02607670 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAT4 Gel
Study NCT02607670 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Study NCT03350542 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYNERGY 48 mm
Description: A drug eluting coronary stent system
Study NCT04010318 — intervention group
Intervention type: PROCEDURE
Intervention: Spinal Anesthesia
Description: The patients will receive spinal block at lumbar 3-4 space with hyperbaric bupivacaine 8 mg plus 25 mic fentanyl. After giving anesthesia and positioning for surgery with a left lateral tilt of 15 degrees, supplemental oxygen at rate of 4 liter/minute is applied.
Study NCT01831284 — intervention group
Intervention type: PROCEDURE
Intervention: Sigmoidoscopy with biopsy
Description: Sigmoidoscopy with biopsy
Study NCT04470258 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: ELMO PROJECT AT COVID-19: STUDY IN HUMANS
Description: The Elmo system will be applied to 10 patients with hypoxemic respiratory failure by COVID-19 and its effectiveness will be assessed by analyzing the physiological variables and the patient's comfort, as well as their clinical outcomes (need for tracheal intubation) and recovery time. Hypoxemic respiratory failure and need for O2.
Study NCT04470258 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ELMO PROJECT AT COVID-19: PROOF OF CONCEPT AND USABILITY
Description: After testing for the following requirements: offering CPAP, ensuring the maintenance of alveolar ventilation without CO2 rebreathing, monitoring intra-ELMO pressure, minimizing adverse effects of the system such as noise, face temperature, airway dryness and comfort global; tests will be carried out on healthy volunteers using prototypes of the Elmo system and assessing whether their effectiveness in providing positive airway pressure and their usability from the perspective of their primary users (doctor, physiotherapist and nurses) and the volunteer's comfort . With this, realistic simulations will be carried out, centered on the evaluation based on heuristic principles.
Study NCT00317226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM)
Description: maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
Study NCT00356265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Procedure: Regional phenylephrine arterial infusion
Study NCT00356265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Procedure: Regional phenylephrine arterial infusion
Study NCT01784653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iMET
Description: Self-completed, computerized motivational enhancement therapy
Study NCT01784653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MET
Description: Clinician-delivered Motivational Enhancement Therapy
Study NCT03957213 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acute Intermittent Hypoxia
Description: Acute intermittent hypoxia is a safe, non-invasive technique. All sessions will be monitored by research study staff trained in delivering acute intermittent hypoxia. Hypoxic intervals will be delivered with a commercially available sports performance hypoxicator. A unit capable of delivering a fraction of inspired oxygen ranging from 21%-9% will be used. Air will be delivered into a mask that will be secured comfortably over the subject's nose and mouth. Intervention sessions will occur for 10 days over a 2 week period.
Study NCT03957213 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Cognitive Training
Description: 60 minutes of Double Decision cognitive training for 10 days over a 2 week period.
Study NCT03957213 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computerized Cognitive Training
Description: 60 minutes of Double Decision cognitive training for 10 days over a 2 week period.
Study NCT06390826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT02303886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue
Description: In NaCL0.9% 100 ml
Study NCT02303886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylene blue
Description: In NaCL0.9% 100 ml
Study NCT02303886 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene blue
Description: in NaCl 0.9% 100 ml
Study NCT02303886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylene blue
Description: in NaCl 0.9% 100 ml
Study NCT01096979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIPO-102
Description: subcutaneous injection
Study NCT01096979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT01220609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Given IV
Study NCT01220609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03471208 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Navigation Assisted Implant Surgery
Description: Implant surgery using dynamic navigation assistance
Study NCT03471208 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Freehand Implant Surgery
Description: Dental implant surgery via conventional freehand
Study NCT00099268 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa/levodopa/entacapone
Description: Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
Study NCT00099268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release carbidopa/levodopa
Description: Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
Study NCT02941510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
Study NCT02941510 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject(s) will participate in all study activities but will receive placebo.
Study NCT01754506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil
Description: EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
Study NCT01754506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fish Oil
Description: EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
Study NCT02563015 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Reference 400
Description: liquid drops
Study NCT00793520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: Twice daily oral administration of Milnacipran for 5 weeks.
Study NCT00793520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Twice daily oral administration of placebo for 5 weeks.
Study NCT06390826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06390826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study NCT06390826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT06390826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT00110188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Study NCT03128684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Small Green Lentil Muffin
Description: Consumption of small green lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
Study NCT03128684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Split Red Lentil Muffin
Description: Consumption of split red lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
Study NCT03128684 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Muffin
Description: Consumption of wheat muffin; consumption of ad libitum pizza test meal after 180 minutes